Lab study finds CBD shifts salinomycin toxicity differently across cell lines

Cannabidiol Differentially Modulates Salinomycin Cytotoxicity in Human Cell Lines.

Molecules (Basel, Switzerland) • • Highly Relevant
🤖

AI Summary

This abstract-based summary describes a laboratory study asking whether cannabidiol (CBD) changes the cytotoxic effects of salinomycin. Researchers tested the compounds alone and in combination in three human cell lines: kidney-derived HEK-293, liver tumor-derived HepG2, and neuroblastoma-derived SH-SY5Y. These were cell experiments, not studies in people or intact organs.

The effect depended on the cell line: CBD attenuated salinomycin’s cytotoxicity in HEK-293 cells, while it enhanced cytotoxicity in the two tumor-derived lines. The reported changes included differences in IC50 values, reactive oxygen species, and measures of cell death. Because all three cell lines were immortalized or tumor-derived, the findings cannot be extrapolated to normal kidney, liver, or neuronal tissue and do not establish a clinical effect. The abstract does not report quantitative effect sizes; these results do not show that CBD is beneficial or harmful in people.

💡 Key Findings

1
In a laboratory study of three human-derived cell lines, CBD modulated salinomycin cytotoxicity differently depending on the cell line.
High
95%
2
In HEK-293 cells, CBD attenuated salinomycin cytotoxicity, with higher reported IC50 values and reduced ROS production.
High
90%
3
In tumor-derived HepG2 and SH-SY5Y cells, CBD enhanced salinomycin cytotoxicity, alongside increased ROS generation and more pronounced cell death.
High
90%
4
Because the tested lines were immortalized or tumor-derived, the findings cannot establish effects in normal kidney, liver, or neuronal tissue, or in people.
High
98%

📄 Original Abstract

Salinomycin, an ionophore coccidiostat widely used in livestock production, has attracted growing interest as a potential anticancer agent, although its clinical application remains limited by pronounced organ-specific toxicity. Cannabidiol (CBD), a non-psychoactive cannabinoid with documented cytoprotective properties, is increasingly consumed, making concurrent exposure plausible, yet its interaction remains unexplored. This study evaluated the cytotoxicity of salinomycin (0.39-50 μg/mL), alone and combined with two non-cytotoxic CBD concentrations (1.56 and 3.125 μg/mL), in three human cell lines-embryonic kidney-derived HEK-293, hepatoblastoma-derived HepG2, and neuroblastoma-derived SH-SY5Y-using assays of mitochondrial and lysosomal activity, membrane integrity, total protein content, and DNA synthesis, complemented by ROS measurement, apoptosis/necrosis evaluation, morphology, and an exploratory combination index analysis. CBD modulated salinomycin cytotoxicity in a strictly cell-line-dependent manner. In HEK-293 cells, it attenuated cytotoxicity, as reflected by uniformly higher IC50 values, reduced ROS production, and lower median fluorescence intensities of Hoechst 33342 and propidium iodide, whereas in the tumor-derived HepG2 and SH-SY5Y lines, it enhanced cytotoxicity irrespective of the CBD concentration applied, accompanied by increased ROS generation and more pronounced cell death. As all three lines are immortalized or tumor-derived, these observations describe cell-line-specific responses and cannot be extrapolated to normal renal, hepatic, or neuronal tissue.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.